Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06707493 · ClinicalTrials.gov registry record · Phase 2
Ivosidenib as Post-HSCT Maintenance for AML
A Phase 2 study of Acute Myeloid Leukemia (AML) and IDH1 Mutation, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT06707493: Recruiting Phase 2 study of Acute Myeloid Leukemia (AML) and IDH1 Mutation, sponsored by Massachusetts General Hospital.
NCT06707493 is a Phase 2 study of Acute Myeloid Leukemia (AML) and IDH1 Mutation that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 75 participants, below the 143-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (48% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06707493, a Phase 2 study of Acute Myeloid Leukemia (AML) and IDH1 Mutation, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
Primary Outcome
Relapse-Free Survival is defined as the time from randomization following transplant to disease relapse or death due to any cause, whichever occurs first. Participants alive without relapse are censored at the date of last seen alive. The primary analysis will be performed using the Kaplan-Meier method with log-rank test.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ivosidenib
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2030-01-01 |
| Phase | Phase 2 |
What NCT06707493 shows while recruiting
NCT06707493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 143-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (48% lower).
The record links to 3 conditions, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06707493 reports a single indexed study location in Massachusetts, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06707493 about?
NCT06707493 is a clinical study titled "Ivosidenib as Post-HSCT Maintenance for AML". This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
What is the current status of trial NCT06707493?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2026-01-16. Estimated completion is 2030-01-01.
What conditions does trial NCT06707493 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML), IDH1 Mutation, Hematopoietic Stem Cell Transplant (HSCT).
What interventions are being tested in trial NCT06707493?
The interventions under investigation include: Placebo (DRUG), Ivosidenib (DRUG).
Who is sponsoring clinical trial NCT06707493?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06707493 being conducted?
This trial has 3 study locations across Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06707493's enrollment target sits among peer trials
75 15th of 29 higher than 15 of 29 other Acute Myeloid Leukemia (AML) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia (AML) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
RECRUITING · Phase 2
-
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
RECRUITING · Phase 2
-
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 2
-
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI